Zheng Quan Zhi Xing·2025-05-13 09:16Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has made adjustments to the general authorization for issuing corporate bonds to enhance the efficiency of the bond issuance process [1][2]. Group 1: Meeting Details - The ninth board of directors held its seventy-ninth meeting on May 12, 2025, with all directors attending via communication [1]. - The meeting complied with the Company Law of the People's Republic of China and relevant regulations [1]. Group 2: Authorization Adjustment - The board approved a resolution to adjust the authorized representatives for the issuance of corporate bonds, allowing the chairman, co-chairman, or vice-chairman to act as authorized representatives [1]. - The previous authorization allowed only the chairman or vice-chairman, which has now been expanded to include the co-chairman [1]. Group 3: Voting Results - The voting results for the resolution showed 12 votes in favor, with no votes against or abstentions [2]. - The revised authorization still requires approval from the shareholders' meeting [2].